These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37980767)

  • 21. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project.
    Gilbert L; Basso O; Sampalis J; Karp I; Martins C; Feng J; Piedimonte S; Quintal L; Ramanakumar AV; Takefman J; Grigorie MS; Artho G; Krishnamurthy S;
    Lancet Oncol; 2012 Mar; 13(3):285-91. PubMed ID: 22257524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival of Women With Type I and II Epithelial Ovarian Cancer Detected by Ultrasound Screening.
    van Nagell JR; Burgess BT; Miller RW; Baldwin L; DeSimone CP; Ueland FR; Huang B; Chen Q; Kryscio RJ; Pavlik EJ
    Obstet Gynecol; 2018 Nov; 132(5):1091-1100. PubMed ID: 30303916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening.
    Menon U; Ryan A; Kalsi J; Gentry-Maharaj A; Dawnay A; Habib M; Apostolidou S; Singh N; Benjamin E; Burnell M; Davies S; Sharma A; Gunu R; Godfrey K; Lopes A; Oram D; Herod J; Williamson K; Seif MW; Jenkins H; Mould T; Woolas R; Murdoch JB; Dobbs S; Amso NN; Leeson S; Cruickshank D; Scott I; Fallowfield L; Widschwendter M; Reynolds K; McGuire A; Campbell S; Parmar M; Skates SJ; Jacobs I
    J Clin Oncol; 2015 Jun; 33(18):2062-71. PubMed ID: 25964255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluation.
    Kearns B; Chilcott J; Whyte S; Preston L; Sadler S
    BMC Med; 2016 Dec; 14(1):200. PubMed ID: 27919292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer.
    Yang WL; Gentry-Maharaj A; Simmons A; Ryan A; Fourkala EO; Lu Z; Baggerly KA; Zhao Y; Lu KH; Bowtell D; Jacobs I; Skates SJ; He WW; Menon U; Bast RC;
    Clin Cancer Res; 2017 Oct; 23(19):5912-5922. PubMed ID: 28637689
    [No Abstract]   [Full Text] [Related]  

  • 26. Psychological morbidity associated with ovarian cancer screening: results from more than 23,000 women in the randomised trial of ovarian cancer screening (UKCTOCS).
    Barrett J; Jenkins V; Farewell V; Menon U; Jacobs I; Kilkerr J; Ryan A; Langridge C; Fallowfield L;
    BJOG; 2014 Aug; 121(9):1071-9. PubMed ID: 24865441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of skirt size and postmenopausal breast cancer risk in older women: a cohort study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Fourkala EO; Burnell M; Cox C; Ryan A; Salter LC; Gentry-Maharaj A; Parmar M; Jacobs I; Menon U
    BMJ Open; 2014 Sep; 4(9):e005400. PubMed ID: 25252818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors affecting visualization of postmenopausal ovaries: descriptive study from the multicenter United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Sharma A; Burnell M; Gentry-Maharaj A; Campbell S; Amso NN; Seif MW; Fletcher G; Brunel C; Turner G; Rangar R; Ryan A; Jacobs I; Menon U;
    Ultrasound Obstet Gynecol; 2013 Oct; 42(4):472-7. PubMed ID: 23456790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psychosocial Factors Associated With Withdrawal From the United Kingdom Collaborative Trial of Ovarian Cancer Screening After 1 Episode of Repeat Screening.
    Jenkins V; Fallowfield L; Langridge C; Barrett J; Ryan A; Jacobs I; Kilkerr J; Menon U; Farewell V
    Int J Gynecol Cancer; 2015 Oct; 25(8):1519-25. PubMed ID: 26222482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insights from UKCTOCS for design, conduct and analyses of large randomised controlled trials.
    Menon U; Gentry-Maharaj A; Burnell M; Apostolidou S; Ryan A; Kalsi JK; Singh N; Fallowfield L; McGuire AJ; Campbell S; Skates SJ; Dawnay A; Parmar M; Jacobs IJ;
    Health Technol Assess; 2023 Aug; ():1-38. PubMed ID: 37843101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Should we screen for ovarian cancer? A commentary on the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) randomized trial.
    Narod SA; Sopik V; Giannakeas V
    Gynecol Oncol; 2016 May; 141(2):191-194. PubMed ID: 26915499
    [No Abstract]   [Full Text] [Related]  

  • 32. Socioeconomic Status and Ovarian Cancer Stage at Diagnosis: A Study Nested Within UKCTOCS.
    Karpinskyj C; Burnell M; Gonzalez-Izquierdo A; Ryan A; Kalsi J; Jacobs I; Parmar M; Menon U; Gentry-Maharaj A
    Diagnostics (Basel); 2020 Feb; 10(2):. PubMed ID: 32046189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening program in ovarian cancer: A logical step in clinical management? A meta-analysis.
    Marchetti C; De Felice F; Perniola G; Lecce F; Vertechy L; Monti M; Musio D; Muzii L; Tombolini V; Benedetti Panici P
    Curr Probl Cancer; 2018; 42(2):235-240. PubMed ID: 29433824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Menon U; McGuire AJ; Raikou M; Ryan A; Davies SK; Burnell M; Gentry-Maharaj A; Kalsi JK; Singh N; Amso NN; Cruickshank D; Dobbs S; Godfrey K; Herod J; Leeson S; Mould T; Murdoch J; Oram D; Scott I; Seif MW; Williamson K; Woolas R; Fallowfield L; Campbell S; Skates SJ; Parmar M; Jacobs IJ
    Br J Cancer; 2017 Aug; 117(5):619-627. PubMed ID: 28742794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule.
    Rosenthal AN; Fraser L; Manchanda R; Badman P; Philpott S; Mozersky J; Hadwin R; Cafferty FH; Benjamin E; Singh N; Evans DG; Eccles DM; Skates SJ; Mackay J; Menon U; Jacobs IJ
    J Clin Oncol; 2013 Jan; 31(1):49-57. PubMed ID: 23213100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ovarian cancer screening: Current status and future directions.
    Nash Z; Menon U
    Best Pract Res Clin Obstet Gynaecol; 2020 May; 65():32-45. PubMed ID: 32273169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality assurance and its impact on ovarian visualization rates in the multicenter United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Sharma A; Burnell M; Gentry-Maharaj A; Campbell S; Amso NN; Seif MW; Fletcher G; Brunell C; Turner G; Rangar R; Ryan A; Jacobs I; Menon U
    Ultrasound Obstet Gynecol; 2016 Feb; 47(2):228-35. PubMed ID: 26095052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ovarian cancer survival by stage, histotype, and pre-diagnostic lifestyle factors, in the prospective UK Million Women Study.
    Gaitskell K; Hermon C; Barnes I; Pirie K; Floud S; Green J; Beral V; Reeves GK;
    Cancer Epidemiol; 2022 Feb; 76():102074. PubMed ID: 34942490
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sonographers' self-reported visualization of normal postmenopausal ovaries on transvaginal ultrasound is not reliable: results of expert review of archived images from UKCTOCS.
    Stott W; Campbell S; Franchini A; Blyuss O; Zaikin A; Ryan A; Jones C; Gentry-Maharaj A; Fletcher G; Kalsi J; Skates S; Parmar M; Amso N; Jacobs I; Menon U
    Ultrasound Obstet Gynecol; 2018 Mar; 51(3):401-408. PubMed ID: 28796383
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.